These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3674250)

  • 21. Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications.
    Kopp SW; Bang HK
    Health Mark Q; 2000; 17(3):39-56. PubMed ID: 11010219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. State-level strategies for reducing prescription drug overdose deaths: Utah's prescription safety program.
    Johnson EM; Porucznik CA; Anderson JW; Rolfs RT
    Pain Med; 2011 Jun; 12 Suppl 2():S66-72. PubMed ID: 21668759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.
    Stafford RS; Furberg CD; Finkelstein SN; Cockburn IM; Alehegn T; Ma J
    JAMA; 2004 Jan; 291(1):54-62. PubMed ID: 14709576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
    Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
    J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physicians asked to write 'No Refill' on propoxyphene Rxes.
    FDA Drug Bull; 1980 Jul; 10(2):11. PubMed ID: 7399191
    [No Abstract]   [Full Text] [Related]  

  • 26. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study.
    Brat GA; Agniel D; Beam A; Yorkgitis B; Bicket M; Homer M; Fox KP; Knecht DB; McMahill-Walraven CN; Palmer N; Kohane I
    BMJ; 2018 Jan; 360():j5790. PubMed ID: 29343479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Boxed warning inconsistencies between drug information resources and the prescribing information.
    Cheng CM; Fu C; Guglielmo BJ; Auerbach AD
    Am J Health Syst Pharm; 2011 Sep; 68(17):1626-31. PubMed ID: 21856808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid Prescribing Rates in Nonmetropolitan and Metropolitan Counties Among Primary Care Providers Using an Electronic Health Record System - United States, 2014-2017.
    García MC; Heilig CM; Lee SH; Faul M; Guy G; Iademarco MF; Hempstead K; Raymond D; Gray J
    MMWR Morb Mortal Wkly Rep; 2019 Jan; 68(2):25-30. PubMed ID: 30653483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid Prescribing: What Are the Numbers?
    Greenblatt DJ
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):6-8. PubMed ID: 29276940
    [No Abstract]   [Full Text] [Related]  

  • 30. Variation among states in prescribing of opioid pain relievers and benzodiazepines--United States, 2012.
    Paulozzi LJ; Mack KA; Hockenberry JM
    J Safety Res; 2014 Dec; 51():125-9. PubMed ID: 25453186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deaths related to propoxyphene or codeine or both.
    Litman RE; Diller J; Nelson F
    J Forensic Sci; 1983 Jan; 28(1):128-38. PubMed ID: 6680732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons.
    Weisberg DF; Becker WC; Fiellin DA; Stannard C
    Int J Drug Policy; 2014 Nov; 25(6):1124-30. PubMed ID: 25190034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New warning on propoxyphene.
    FDA Drug Bull; 1979 Sep; 9(4):22-3. PubMed ID: 488581
    [No Abstract]   [Full Text] [Related]  

  • 35. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why has antibiotic prescribing for respiratory illness declined in primary care? A longitudinal study using the General Practice Research Database.
    Ashworth M; Latinovic R; Charlton J; Cox K; Rowlands G; Gulliford M
    J Public Health (Oxf); 2004 Sep; 26(3):268-74. PubMed ID: 15454595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When drugs in the same controlled substance schedule differ in real-world abuse, should they be differentiated in labeling?
    Dasgupta N; Henningfield JE; Ertischek MD; Schnoll SH
    Drug Alcohol Depend; 2011 Dec; 119(1-2):e1-4. PubMed ID: 21704462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study.
    Tifratene K; Manera V; Fabre R; Gros A; Thummler S; Pradier C; Robert P; David R
    Alzheimers Res Ther; 2017 Apr; 9(1):34. PubMed ID: 28446209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in the medical management of patients on opioid analgesics following a diagnosis of substance abuse.
    Paulozzi LJ; Zhou C; Jones CM; Xu L; Florence CS
    Pharmacoepidemiol Drug Saf; 2016 May; 25(5):545-52. PubMed ID: 26861165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.